Metastatic Gastric (Stomach) Cancer Evaluation & Personalized Systemic Treatment Strategy at Sheba Hospital- JCI accreditated and Top-10 Hospitals 2025 by Newsweek

• PET-CT検査
• 腫瘍専門医の診察
• 病理組織検査
• 免疫療法
• 化学療法
• 血液検査

• 12 日 ホテルで

• 移送は含まれていません

Advanced Metastatic Stomach Cancer Evaluation & Personalized Systemic Treatment Strategy
Overview
This program is designed for patients diagnosed with metastatic gastric signet-ring cell carcinoma, requiring comprehensive evaluation and development of an individualized systemic treatment strategy.
Treatment is provided at Sheba Medical Center — a Top-10 globally ranked hospital, with extensive experience in advanced gastrointestinal oncology.
Clinical Situation
Metastatic gastric cancer, particularly signet-ring cell subtype, is a biologically aggressive disease that requires:
precise staging
molecular profiling
multidisciplinary decision-making
In most cases, treatment is systemic (chemotherapy / targeted therapy / immunotherapy) rather than surgical.
Program Structure
Comprehensive On-Site Assessment (5–7 days)
The program begins with a detailed diagnostic phase to confirm disease extent and define treatment options:
Advanced imaging review (CT / PET-CT)
Laboratory panel including tumor markers (CEA, CA 19-9, CA 125)
Full biochemical and hematologic profile
Pathology review
Multidisciplinary consultations:
GI oncologist
radiologist
cardiologist
neurologist (if indicated)
additional specialists as required
Molecular & Genetic Profiling (if indicated)
To guide targeted therapy, additional testing may include:
BRAF, KRAS, NRAS mutations
MMR / MSI status
FISH testing
This step is critical for identifying patients who may benefit from personalized or targeted treatments
Personalized Oncology Treatment Strategy
Following evaluation, a customized treatment plan is developed, which may include:
systemic chemotherapy
targeted therapy
immunotherapy
supportive and symptom-oriented care
Key Advantages

Expertise in advanced and metastatic gastric cancer
Personalized treatment plan after on-site evaluation
Access to molecular diagnostics and targeted therapies
Multidisciplinary tumor board decision-making
Strategy focused on optimizing outcomes and avoiding ineffective treatments
Estimated Timeline
Diagnostic phase: 5–7 working days
Treatment initiation: immediately after plan confirmation
Estimated Costs
Comprehensive assessment: ~$2,400 – $4,200
Additional molecular testing: ~$500 – $4,000
Systemic therapy (per cycle): ~$1,800 – $4,000
Final cost is determined after in-person evaluation.
Important Note
The exact treatment strategy, including:
type of systemic therapy
need for additional testing
treatment sequence
is defined only after full diagnostic evaluation and multidisciplinary review

• 専任医療コーディネーター
• 医療旅行手配 — 特別パートナー価格での航空券・ホテル予約
• 医療旅行中の患者擁護